Published results of NuBiyota’s first clinical trial
Category: Publications
Bugs as drugs: The role of microbiome in cancer focusing on immunotherapeutics
A recent review from NuBiyota’s clinical partners discussing how the microbiome may be used to modulate response to cancer chemotherapy .
Drivers of human gut microbial community assembly: coadaptation, determinism and stochasticity
Research from the Allen-Vercoe laboratory describing the potential importance of co-adaptation within a microbial community to its establishment within the human gut.
Effects of defined gut microbial ecosystem components on virulence determinants of Clostridioides difficile
Research from the Allen-Vercoe lab to further define aspects of METs which have antagonistic effects on C. difficile bacteria.
Fecal Microbiota-based Therapeutics for Recurrent Clostridium difficile Infection, Ulcerative Colitis and Obesity
A review article discussing the evolution of FMT and MET for the treatment of several diseases.
A human gut ecosystem protects against C. difficile disease by targeting TcdA
Research that showcases some of the work done to define one of the mechanisms through which METs are effective against C. difficile infection.
Using bugs as drugs: microbial ecosystem therapeutics
A commentary on the development of defined gut microbial ecosystems as Microbial Ecosystem Therapeutics (METs), a cornerstone of NuBiyota’s technology.
Simulating distal gut mucosal and luminal communities using packed-column biofilm reactors and an in vitro chemostat model
The early papers from the Allen-Vercoe lab that outline the development of methods to simulate the distal gut environment in vitro, allowing the powerful study of gut microbial communities.
Ecobiotherapy Rich in Firmicutes Decreases Susceptibility to Colitis in a Humanized Gnotobiotic Mouse Model
Collaborative work with the Verdu lab (McMaster University, Canada) to show the effectiveness of the MET approach in vivo.
Artificial stool transplantation: progress towards a safer, more effective and acceptable alternative
A short editorial discussing the merits of defined microbial ecosystems for the treatment of diseases.